A new approach for optimizing empirical prescriptions of famous physicians based on network target: taking Qingluo Decoction as an example.
10.19540/j.cnki.cjcmm.20220613.704
- Author:
Yan LI
1
;
Xin WANG
2
;
Zhe YANG
1
;
Nan-Xi LIAO
1
;
Yi-Wei WANG
1
;
Chao-Fan JI
1
;
Shao LI
2
Author Information
1. Xin'an Medical Research Center, Wannan Medical College, Anhui Famous Traditional Chinese Medicine LI Yan Studio Wuhu 241000, China.
2. Department of Automation, Tsinghua University, Institute for TCM-X Beijing 100084, China.
- Publication Type:Journal Article
- Keywords:
angiogenesis;
modified Qingluo Decoction;
network pharmacology;
network target;
rheumatoid arthritis
- MeSH:
Humans;
Medicine, Chinese Traditional;
Drugs, Chinese Herbal/therapeutic use*;
Vascular Endothelial Growth Factor A;
Prescriptions;
Physicians
- From:
China Journal of Chinese Materia Medica
2022;47(19):5264-5273
- CountryChina
- Language:Chinese
-
Abstract:
Based on the network target approach and technology, this study proposed for the first time a novel optimization method for Chinese medicine formulae. Moreover, with Qingluo Decoction as an example, a method for the research and development of Chinese medicine, which combines scientific methodology and experience of famous doctors, was developed. Specifically, based on the composition of Qingluo Decoction, this study used the using network target for intelligent and quantitative analysis on drug actions(UNIQ) to predict the medicinals that targeted the key pathways of rheumatoid arthritis(RA) such as angiogenesis. Then, combining the experience of the first national Chinese medical master LI Ji-ren and Aihui famous Chinese medicine doctor LI Yan and Chinese medicine theory, this study developed a novel angiogenesis-targeted prescription modified Qingluo Decoction(MQLD). Afterward, the clinical efficacy and mechanism of MQLD were verified. The results showed that 27 medicinals with significant regulatory effect on angiogenesis-related key signaling pathways were identified by UNIQ, among which 6 were selected by the Chinese medicine physicians to develop the MQLD. Clinical trials demonstrated that the clinical efficacy of MQLD, in terms of either American College of Rheumatology 20% improvement and 50% improvement criteria(ACR20, ACR50) or TCM syndrome evaluation, was better than that of Qingluo Decoction. Experimental study revealed that MQLD can inhibit RA angiogenesis by acting on the vascular endothelial growth factor(VEGF) pathway, nuclear factor κB(NF-κB) pathway, inflammatory cytokine release, and immune cell regulation. Taken together, this study developed a new formula MQLD with improved clinical efficacy, precise applicable clinical settings, and authorized patent through the network target technology, thus providing a new way for the precise development of Chinese medicine and preservation of the experience of famous physicians.
